Orchid Pharma Limited (NSE:ORCHPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 38.90B |
| Revenue (ttm) | 9.02B |
| Net Income (ttm) | 1.11B |
| Shares Out | 50.72M |
| EPS (ttm) | 21.87 |
| PE Ratio | 35.08 |
| Forward PE | 29.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,463 |
| Average Volume | 67,065 |
| Open | 775.00 |
| Previous Close | 767.05 |
| Day's Range | 758.55 - 799.00 |
| 52-Week Range | 684.35 - 1,997.40 |
| Beta | 1.95 |
| RSI | 40.47 |
| Earnings Date | May 30, 2025 |
About Orchid Pharma
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile product... [Read more]
Financial Performance
In 2023, Orchid Pharma's revenue was 8.19 billion, an increase of 23.05% compared to the previous year's 6.66 billion. Earnings were 921.67 million, an increase of 98.99%.
Financial StatementsNews
Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility
Orchid Pharma Ltd. saw a 4% jump in its stock price following the successful completion of a surprise inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical ...
Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal
Orchid Pharma Limited has announced the successful completion of a surprise USFDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection...
Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3
Orchid Pharma witnessed a sharp decline of over 14% in its stock price after the company reported weak financial results for Q3. As of 10:27 AM, the shares were trading 14.78% lower at Rs 1,051.65. Fo...
Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results
Orchid Pharma shares rose by 3.94%, trading at ₹1,509.90 on the NSE as of 11:29 am, driven by impressive Q2 FY25 financial results showcasing robust growth in revenue and profitability. Key Financial ...
Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY
Orchid Pharma announced its Q2 FY25 results, reflecting strong growth in revenue and profitability. The company continues to benefit from efficient cost management and operational improvements, leadin...